bavarostat

Bavarostat is a highly selective and brain-penetrant small molecule inhibitor of histone deacetylase 6 (HDAC6). It demonstrates over 80-fold selectivity for HDAC6 compared to other zinc-containing HDAC paralogues. Bavarostat modulates tubulin acetylation selectively over histone acetylation and has been developed as both a therapeutic candidate and as a radiolabeled positron emission tomography (PET) imaging agent ([18F]bavarostat) for mapping HDAC6 in the living brain. Its primary research focus is on central nervous system disorders such as alcohol use disorder and post-traumatic stress disorder, with additional interest in neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, Rett syndrome, major depressive disorder, motor neuron disease, and certain cancers. The drug was originally developed by Eikonizo Therapeutics.

Other names

HDAC6 antagonist PET tracerHDAC-6 antagonist PET tracerHDAC 6 antagonist PET traceranti-HDAC6 PET traceranti-HDAC-6 PET traceranti-HDAC 6 PET tracer